Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment

被引:46
作者
Relhan, Nidhi [1 ]
Albini, Thomas A. [1 ]
Pathengay, Avinash [2 ]
Kuriyan, Ajay E. [1 ]
Miller, Darlene [1 ]
Flynn, Harry W. [1 ]
机构
[1] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA
[2] LV Prasad Eye Inst, Retina & Uveitis Dept, GMR Varalakshmi Campus, Visakhapatnam, Andhra Pradesh, India
基金
美国国家卫生研究院;
关键词
RESISTANT STAPHYLOCOCCUS-AUREUS; POSTOPERATIVE ENDOPHTHALMITIS; ENTEROCOCCUS-FAECIUM; ENDOGENOUS ENDOPHTHALMITIS; INTRAVITREAL INJECTION; IRRIGATING SOLUTIONS; OCULAR PENETRATION; CATARACT-SURGERY; RABBIT MODEL; QUINUPRISTIN/DALFOPRISTIN;
D O I
10.1136/bjophthalmol-2015-307722
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility and/or resistance is an important clinical issue worldwide. Purpose To review the published literature on endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility and/or vancomycin resistance. Methods The data were analysed from a PubMed search of endophthalmitis cases caused by Gram-positive organisms with reported reduced vancomycin susceptibility and/or vancomycin resistance from 1990 to 2015. Results From 18 publications identified, a total of 27 endophthalmitis cases caused by Gram-positive organisms with reduced vancomycin susceptibility and/or vancomycin resistance were identified. The aetiologies of endophthalmitis were exogenous in 19/27 cases (11 post-cataract surgery, 2 post-penetrating keratoplasty, 1 post-glaucoma surgery, 4 post-open globe injury, 1 post-intravitreal injection of ranibizumab), and endogenous in 4/24 cases; no details were available about the four remaining patients. The causative organisms included Enterococcus species (7/27), coagulase-negative staphylococci (4/27), Staphylococcus aureus (4/27), Bacillus species (4/27), Streptococcus species (3/27), Leuconostoc species (3/27), Staphylococcus hominis (1/27), and unidentified Gram-positive cocci (1/27). Visual acuity of 20/400 or better at the final follow-up was recorded in 10/26 patients (38.5%; data were not available for one patient). Treatment options include fluoroquinolones, penicillin, cephalosporins, tetracyclines, and oxazolidinones. Conclusions In the current study, visual acuity outcomes were generally poor. Enterococcus and Staphylococcus species were the most common organisms reported and postoperative endophthalmitis after cataract surgery was the most common clinical setting.
引用
收藏
页码:446 / 452
页数:7
相关论文
共 74 条
[1]  
Anijeet DR, 2010, CLIN OPHTHALMOL, V4, P321
[2]  
[Anonymous], 1994, Fed Regist, V59, P25758
[3]   GENETICS AND MECHANISMS OF GLYCOPEPTIDE RESISTANCE IN ENTEROCOCCI [J].
ARTHUR, M ;
COURVALIN, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) :1563-1571
[4]   In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci [J].
Auckenthaler, R ;
Courvalin, P ;
Féger, C ;
Roche, G .
CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (11) :608-612
[5]   Postoperative vancomycin-resistant Enterococcus faecium endophthalmitis [J].
Bains, Harshivinderjit S. ;
Weinberg, David V. ;
Feder, Robert S. ;
Noskin, Gary A. .
ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (09) :1292-1293
[6]   EVALUATION OF TEICOPLANIN AND VANCOMYCIN DISK SUSCEPTIBILITY TESTS [J].
BARRY, AL ;
THORNSBERRY, C ;
JONES, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 1986, 23 (01) :100-103
[7]   Intravitreal Daptomycin in a Case of Bilateral Endogenous Endophthalmitis [J].
Buzzacco, Dominic M. ;
Carroll, C. Patrick .
ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (07) :940-941
[8]   Vancomycin-resistant enterococci [J].
Cetinkaya, Y ;
Falk, P ;
Mayhall, CG .
CLINICAL MICROBIOLOGY REVIEWS, 2000, 13 (04) :686-+
[9]   INVITRO EVALUATION OF CEFPIROME (HR 810), TEICOPLANIN AND 4 OTHER ANTIMICROBIALS AGAINST ENTEROCOCCI [J].
CHANDRASEKAR, PH ;
PRICE, S ;
LEVINE, DP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 16 (02) :179-182
[10]  
*CLIN LAB STAND I, 2006, PERF STAND ANT SUS S, V26